Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management
Using empagliflozin in patients with heart failure, reduced ejection fraction
Using empagliflozin in patients with heart failure, reduced ejection fraction
![Fragile](/sites/default/files/styles/cropped_image_16_7_/public/2022-03/Fragile_Kevin-Woblick-_on_Unsplash.jpg?itok=rFd1dJm7)
Pharmacist prescriber Penny Clark reviews the evidence for the benefit of empagliflozin in patients with heart failure, and highlights some factors to consider when implementing it alongside other cardiovascular and diabetes drugs
1. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383(15):1413–24.
2. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381(21):1995–2008.
3. Butler J, Usman MS, Khan MS, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail 2020;7(6):3298–309.
4. Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 2021;42(6):671–80.
5. Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol 2021;77(11):1397–407.
6. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451–61.